Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines fighting against infectious disease, cancer and autoimmune conditions, faster and more efficiently than the industry standard.

With the commercialization of mRNA vaccines against COVID-19, research and development into the application of mRNA in vaccines and pharmaceuticals is accelerating. In particular, it is attracting attention not only in vaccines for preventing infectious diseases but also in cancer immunotherapy.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its growing cancer therapy pipeline.

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines to fight infectious diseases,